WCLC 2025 - Posters & ePosters-EP.18.09 Adebrelimab Beyond Progression Plus Chemotherapy or Targeted Therapy as Second-Line Treatment for Extensive-Stage Small Cell Lung Cancer

EP.18.09 Adebrelimab Beyond Progression Plus Chemotherapy or Targeted Therapy as Second-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Back to course

Pdf Summary

The ABLE trial is a prospective, single-arm exploratory study evaluating the efficacy and safety of continuing adebrelimab treatment beyond disease progression combined with chemotherapy or targeted therapy as a second-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The trial targets adult patients (aged 18–80) with histologically or cytologically confirmed ES-SCLC who have disease progression following first-line therapy with adebrelimab plus chemotherapy, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, measurable lesions per RECIST 1.1 criteria, and adequate organ function.<br /><br />Building on data from previous studies, such as the phase III IMfirst and ASTRUM-005 trials, which suggested survival benefits from continuing immune checkpoint inhibitors like atezolizumab or serplulimab beyond progression, the ABLE trial investigates whether continuing adebrelimab combined with chemotherapy or targeted therapies improves outcomes in this setting. The rationale is supported by the Cancer-Immunity Cycle theory, proposing synergistic anti-tumor effects from combining immune checkpoint inhibitors with other treatments.<br /><br />The primary endpoint of the trial is progression-free survival (PFS). Secondary endpoints include objective response rate (ORR), disease control rate (DCR), duration of response (DoR), overall survival (OS), and safety. The study also explores correlations between T-cell subpopulations, nutritional indicators, and therapeutic efficacy.<br /><br />Patients receive adebrelimab (1200 mg or 20 mg/kg intravenously every three weeks) alongside chemotherapy, targeted therapy, or other regimens selected per investigator discretion. The trial is registered under ChiCTR2400093930.<br /><br />This study addresses the current lack of effective second-line therapies for ES-SCLC and evaluates the potential clinical benefit of continuing immunotherapy beyond progression combined with other agents to improve patient outcomes.

Asset Subtitle

Yuan Liang

Meta Tag

Speaker Yuan Liang

Topic Clinical Trials in Progress

Keywords

ABLE trial

adebrelimab

extensive-stage small cell lung cancer

second-line treatment

immune checkpoint inhibitors

progression-free survival

chemotherapy

targeted therapy

phase III trials

T-cell subpopulations